Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company specializing in complex rare disease treatments, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami Beach, FL.
The company's management team will deliver a presentation on Monday, March 10, 2025, from 3:40 to 4:10 PM EST and engage in one-on-one investor meetings throughout the conference, which runs from March 10-12, 2025. The presentation will be accessible via webcast, and a replay will remain available for 30 days on Larimar's website under the 'Events and Presentations' section.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LRMR gained 5.28%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
Details on the presentation can be found below.
Date: Monday, March 10, 2025
Time: 3:40 – 4:10 PM EST
Webcast Link: https://wsw.com/webcast/leerink38/lrmr/2247553
Following the conclusion of the presentation, a replay will be available for 30 days on the “Events and Presentations” page of Larimar’s website.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
When is Larimar Therapeutics (LRMR) presenting at the Leerink Partners Conference 2025?
How can investors watch Larimar Therapeutics' (LRMR) Leerink Conference presentation?
What type of meetings will LRMR management conduct at the 2025 Leerink Conference?
How long will the LRMR Leerink Conference presentation replay be available?
